Lv4
700 积分 2022-04-27 加入
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1个月前
已完结
Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports
1个月前
已完结
Molecular Insights Into the Origin, Biology, and Treatment of Anaplastic Thyroid Carcinoma
2个月前
已关闭
The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors
2个月前
已完结
The Role of Molecular Markers in Thyroid Cancer Diagnostics and Treatment
2个月前
已完结
Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis
3个月前
已完结
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions
3个月前
已完结
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
3个月前
已完结
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
3个月前
已完结
In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation
3个月前
已完结
皖公网安备34019202002308
